Padcev (enfortumab vedotin)

Numéro de dossier de l’APP: 21705
État des négociations:
Active Negotiation
Indication(s):
Treatment of patients with locally advanced or metastatic urothelial cancer (mUC) who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and who: have received a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting or are not eligible for cisplatin-containing chemotherapy
Promoteur/fabricant:
Seagen Canada Inc.
Numéro de projet de l’ACMTS:
PC0251-000
Lettre-contrat de l’APP:
Conclusion du processus de négociation:
Not Applicable